UNSPSC 51241500: Combination antiglaucoma, ophthalmic, and eye-related agents and preparations

This classification denotes a) combination drugs that treat an ocular disease characterized by increase in intraocular pressure which the eye cannot withstand without damage to its structure or functional impairment, called GLAUCOMA, hence the term ANTIGLAUCOMA PREPARATIONS; b) combination drugs that treat diseases of the eyes, or in the field of ophthalmology, hence the term OPHTHALMIC AGENTS, which include anesthetic, anti-allergy, antibacterial, corticosteroid, and mydriatic drugs; c) eye-related agents, which include artificial tears, eye washes, and the like, hence the term eye-related agents.

Typical combination antiglaucoma, ophthalmic, and eye-related agent constituents are antazoline, brimonidine, carboxymethylcellulose, dorzolamide, epinephrine, hydroxyethyl cellulose, hypromellose, and tetrahydrozoline.

UNSPSC 51241500 Combination antiglaucoma, ophthalmic, and eye-related agents and preparations is a Class code covering pharmaceutical products and formulations used to treat glaucoma and related ocular conditions, procured by state and local health departments, corrections departments, and public health agencies for inmate populations, community health clinics, and emergency medical services. State and local governments acquire these products as part of standardized pharmaceutical inventory for hospitals, correctional facilities, and outpatient clinics, where they support ongoing patient care and chronic disease management. The mix of issuing bodies reflects the breadth of public healthcare delivery: state health and human services departments, county health departments, city public health agencies, and state corrections systems all procure antiglaucoma and ophthalmic preparations as components of broader pharmaceutical contracts or standalone specialty-medication buys.

The source provides no recent state and local contract opportunities posted under this code, limiting visibility into current geographic activity, issuing-body concentration, or representative procurement patterns. Without posted solicitations in the recent-opportunities data, the code's activity level and the types of notice structures (RFP, RFQ, IFB, or ITT) state and local buyers are using cannot be characterized. Firms evaluating entry into antiglaucoma and ophthalmic-agent procurement at the state and local level should monitor cooperative purchasing agreements through established state pharmaceutical-contracting vehicles and standing schedules, which often serve as de facto procurement pathways for specialty medications in this therapeutic class.